Retina Foundation Presents at Largest Retina Meeting in China
Retina China 2018, a prestigious meeting held March 28-30 in Qingdao, China, was well attended by retinal specialists from all over Asia with only a handful invited from the United States, including Dr. Karl Csaky, Managing & Medical Director of the Retina Foundation of the Southwest. Having been invited to present at this meeting, Dr. Csaky used this opportunity to speak about the new OCT-A machine recently acquired by the Retina Foundation. This new cutting-edge technology enables our researchers to obtain detailed information on the retinal layers, blood vessels, blood flow, and more in patients with age-related macular degeneration. Dr. Csaky’s talk highlighted the importance of this new technology in helping diagnose and treat patients with age-related macular degeneration.
About Dr. Karl G. Casky
Karl G. Csaky, M.D., Ph.D. is the Managing & Medical Director, Director of the Molecular Ophthalmology Laboratory, and the T. Boone Pickens Senior Scientist at the Retina Foundation of the Southwest. Dr. Csaky’s main area of research is age-related macular degeneration, on which he conducts both laboratory and clinical research.
About Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the number one cause of vision loss for people over the age of 65. It is a common retinal disease that disrupts the central vision that is necessary for everyday tasks such as reading, writing, and driving. Age-related macular degeneration occurs when there is a loss of visual cells (rods and cones) from the macula, the central part of the retina.
![Retina Foundation Presents at Largest Retina Meeting in China Retina Foundation Presents at Largest Retina Meeting in China](https://retinafoundation.org/wp-content/uploads/2018/04/Dr.-Csaky-1-e1522792754892.jpg)
Related Articles
Introducing the Vision and Neurodevelopment Laboratory Investigating the Impact of Lazy Eye on Reading Speed and Motor Skills in Children – Video Update Macular Degeneration Stem Cell Clinical Trial Results Allow for Phase II Expansion FFB Pledges $300,000 to Support Dr. Yi-Zhong Wang’s Artificial Intelligence/ Deep Machine Learning Project Meet Sharon and Harold Hosack